Close Menu

NEW YORK (360Dx) – Genomic Health and Cleveland Diagnostics today announced a licensing agreement to develop and commercialize prostate cancer tests based on Cleveland Diagnostics' IsoPSA reagents and technology.

The strategic collaboration will provide Genomic Health with "broad exclusive global rights" to develop and commercialize early- and late-stage cancer diagnostic tests, the firms said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.